NCT04144777

Brief Summary

Solarplast is a unique mixture of antioxidant enzymes and single antioxidant molecules that are capable of attack oxidants that cause damage to the cells in the human body and cause premature aging. This mechanism may provide protection from stress, such as free radicals, heat, infection, as well as reduce inflammation and participate in the repair mechanism of the intestinal tract. Participants will consume Solarplast, or placebo, for 45 days with blood draws at day-0 and -45 in order to assess antioxidant capacity.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
84

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jul 2019

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 15, 2019

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

October 23, 2019

Completed
7 days until next milestone

First Posted

Study publicly available on registry

October 30, 2019

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2020

Completed
Last Updated

February 15, 2021

Status Verified

October 1, 2019

Enrollment Period

10 months

First QC Date

October 23, 2019

Last Update Submit

February 12, 2021

Conditions

Keywords

SmokersPrediabetesCognitive Health

Outcome Measures

Primary Outcomes (4)

  • Oxidative Stress

    Analyze change in reactive oxygen species obtained from blood from baseline to 45 days using reactive oxygen species testing kits

    45 days

  • Blood glucose

    Analyze change in fasting blood glucose obtained from blood from baseline to 45 days using metabolic panel

    45 days

  • Change in skin health using questionnaires

    Analyze skin health using questionnaires

    45 days

  • Change in joint pain using questionnaires

    Analyze change in joint pain using questionnaires

    45 days

Study Arms (2)

Treatment

EXPERIMENTAL

Subjects will be administered one daily dose of Solarplast (100mg), in a capsule, for 45 days.

Dietary Supplement: Solarplast

Placebo

NO INTERVENTION

Subjects will be administered one daily dose of maltodextrin (100mg), in a capsule, for 45 days.

Interventions

SolarplastDIETARY_SUPPLEMENT

Subjects will take one capsule of Solarplast (100mg) daily for 45 days.

Treatment

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Healthy smokers
  • Healthy non-smokers
  • Prediabetics (elevated fasting blood glucose of 100-125mg/dL).

You may not qualify if:

  • No specific pulmonary disease
  • No medication or specifically any inhaled bronchodilators or corticosteroids.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Kennesaw State University

Kennesaw, Georgia, 30144, United States

Location

MeSH Terms

Conditions

Prediabetic State

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System Diseases

Study Officials

  • Trisha VanDusseldorp, PhD

    Kennesaw State University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
BASIC SCIENCE
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 23, 2019

First Posted

October 30, 2019

Study Start

July 15, 2019

Primary Completion

May 1, 2020

Study Completion

May 1, 2020

Last Updated

February 15, 2021

Record last verified: 2019-10

Data Sharing

IPD Sharing
Will not share

Locations